Entering the ADC game with DualityBio partnership
The company announced a strategic partnership with Duality Bio to develop antibody drug conjugates (ADCs) for solid tumours. BioNTech will in-license two ADCs, DB-1303 and DB-1311, for the upfront payment of USD 170m and development, regulatory and commercial milestone payments over USD 1.5bn, as w
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.